Natalizumab: all 58 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingNCT07892027Phase 2
• Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)RecruitingNCT05418010Phase 2
• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple SclerosisTerminatedNCT05265728Phase 3Results posted
• Natalizumab and Chronic InflammationTerminatedNCT05177718Phase 4Results posted
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationCompletedNCT03689972Phase 3Results posted
• Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal EpilepsyCompletedNCT03283371Phase 2Results posted
• Natalizumab in Preventing Post-partum Relapses in Multiple SclerosisCompletedNCT03046251Phase 4Results posted
• Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic StrokeCompletedNCT02730455Phase 2Results posted
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsTerminatedNCT02342704Phase 4Results posted
• Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other TherapiesTerminatedNCT02241785Phase 4Results posted
• Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHDCompletedNCT02176031Phase 2Results posted
• Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host DiseaseCompletedNCT02133924Phase 2Results posted
• Effect of Natalizumab on Infarct Volume in Acute Ischemic StrokeCompletedNCT01955707Phase 2Results posted
• The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple SclerosisCompletedNCT01455220Not applicableResults posted
• Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT01440101Phase 2/3Results posted
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisTerminatedNCT01416181Phase 3Results posted
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01416155Phase 2Results posted
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)CompletedNCT01405820Phase 2Results posted
• Tysabri Effects on Cognition and Neurodegeneration in Multiple SclerosisCompletedNCT01071512Not applicableResults posted
• Treatment Interruption of NatalizumabCompletedNCT01071083Phase 2Results posted
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedNCT01058005Phase 3Results posted
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00871780Phase 4Results posted
• Study of Natalizumab in Relapsed/Refractory Multiple MyelomaTerminatedNCT00675428Phase 1/2Results posted
• The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple SclerosisCompletedNCT00536120Phase 4Results posted
• Natalizumab High Titer Immunogenicity and SafetyCompletedNCT00516893Phase 2Results posted
• Natalizumab Re-Initiation of DosingCompletedNCT00306592Phase 3Results posted
• Natalizumab (Tysabri) Re-Initiation of DosingTerminatedNCT00297232Phase 3Results posted
• Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving MethotrexateTerminatedNCT00083759Phase 2Results posted
• Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)CompletedNCT05618301Phase 1
• A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT05532163Phase 4
• Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic OsteosarcomaWithdrawnNCT03811886Phase 1/2
• Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSActive, not recruitingNCT03535298Phase 4
• Towards Personalized Dosing of Natalizumab in Multiple SclerosisCompletedNCT03516526Phase 4
• Inflammatory Response In SchizophreniaCompletedNCT03093064Phase 1
• Methylprednisolone During the Switch Between Natalizumab and FingolimodStatus unknownNCT02769689Phase 4
• Natalizumab in Inclusion Body Myositis (IBM)Status unknownNCT02483845Phase 1
• Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to GilenyaStatus unknownNCT02325440Phase 4
• Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02142205Phase 4
• Natalizumab Subcutaneous Immunogenicity and Safety StudyTerminatedNCT02142192Phase 2
• PK and PD Study of Natalizumab in Pediatric Subjects With RRMSCompletedNCT01884935Phase 1
• NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or SleepinessCompletedNCT01591551Phase 4
• Natalizumab Treatment of Progressive Multiple SclerosisCompletedNCT01077466Phase 2
• Biomarkers and Response to Natalizumab for Multiple Sclerosis TreatmentCompletedNCT00942214Phase 4
• A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201TerminatedNCT00831649Phase 2
• Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α TherapyWithdrawnNCT00801125Phase 4
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnNCT00771043Phase 4
• A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady StateCompletedNCT00744679Phase 4
• Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)CompletedNCT00559702Phase 1
• Open Label Natalizumab Safety Extension Study for Subjects With Crohn's DiseaseCompletedNCT00280956Phase 4
• Open-Label Natalizumab Safety Extension StudyCompletedNCT00276172Phase 3
• Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00097760Phase 2
• A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's DiseaseCompletedNCT00078611Phase 3
• Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's DiseaseCompletedNCT00055536Phase 2
• Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's DiseaseCompletedNCT00055367Phase 2
• Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseaseCompletedNCT00032799Phase 3
• Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseaseCompletedNCT00032786Phase 3
• Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple SclerosisCompletedNCT00030966Phase 3
• Safety and Efficacy of Natalizumab in the Treatment of Multiple SclerosisCompletedNCT00027300Phase 3

← Natalizumab overview